Skip to main content
SpringerLink
Log in

Prevention of Hepatitis A

  • Chapter
  • First Online:
Viral Hepatitis in Children

  • 366 Accesses

Abstract

Hepatitis A virus (HAV) infection is a preventable, acute inflammatory disease of the liver caused by a member of the Picornavirus family. The HAV is a non-cytopatic, hepato-trophic RNA virus which replicates in hepatocytes and generates immune-mediated liver injury. Infection is mainly transmitted through fecal-oral route, close person-to-person contact, and intake of contaminated water or food. HAV endemicity is classified as high, intermediate, low, and very low, depending on age-adjusted prevalence of anti-HAV(IgG) antibodies in the population. The epidemiology and susceptibility to infection are driven by a number of factors including sanitary and socioeconomic conditions, age at exposure, and herd immunity. Improvement in socioeconomic conditions and in the level of hygienic standards in many countries with intermediate endemicity in transition has led to a shift in susceptibility to infection in adolescents and young adults. Major progress has been made in the past decades in prevention of hepatitis A. Pre- and postexposure prophylaxis using formaldehyde-inactivated HAV vaccines has gradually replaced the use of immune serum globulin for protection of subjects at risk. Live attenuated HAV vaccines have been developed in China for preexposure prophylaxis. Several attenuated HAV strains have been used for over 20 years in the United States, Europe, and China for manufacturing of formalin-inactivated vaccines. Administration of such highly immunogenic vaccines, given at two doses, separated by a flexible interval of 6–12 months, has had an excellent record of safety and tolerability. While most countries still employ a two-dose immunization strategy, Argentina and China chose to use a single-dose immunization strategy for UMV, using a formaldehyde-inactivated and live attenuated vaccine, respectively. Immunization strategies include universal mass vaccination (UMV) of toddlers, regional mass vaccination (RMV), and immunization of distinct risk groups. Introduction of UMV and RMV programs in the United States, Israel, several European countries, and in Australia has led to an unprecedented decline in the incidence of HAV infection and a rise in herd immunity in these regions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACIP:

Advisory Committee on Immunization Practices

AE:

Adverse event

Anti-HAV:

Antibodies to the hepatitis A virus

CDC:

Centers for Disease Control

EPI:

Expanded program of immunization

HAV:

Hepatitis A virus

IG:

Immune globulin

IgA:

Immune globulin A

IgG:

Immune globulin G

IgM:

Immune globulin M

MMR:

Mumps, measles, and rubella vaccine

MSM:

Men who have sex with men

PEP:

Postexposure prophylaxis

RMV:

Regional mass vaccination

SAE:

Serious adverse event

UMV:

Universal mass vaccination

WHO:

World Health Organization

References

  1. Siegl G, Weitz M, Kronauer G (1984) Stability of hepatitis A virus. Intervirology 22(4):218–226

    Article  CAS  PubMed  Google Scholar 

  2. Liu JP, Nikolova D, Fei Y (2009) Immunoglobulins for preventing hepatitis A. Cochrane Database Syst Rev 2:CD004181

    Google Scholar 

  3. Shouval D (2010) Hepatitis A. The immunological basis for immunization series. Module 18,World Health Organization. http://whqlibdoc.who.int/publications/2011/9789241501422_eng.pdf

  4. Tejada-Strop A, Costafreda MI, Dimitrova Z, Kaplan GG, Teo CG (2017) Evaluation of potencies of immune globulin products against hepatitis A. JAMA Intern Med 177(3):430–432

    Article  PubMed  Google Scholar 

  5. Zhang RL, Zeng JS, Zhang HZ (1990) Survey of 34 pregnant women with hepatitis A and their neonates. Chin Med J 103(7):552–555

    CAS  PubMed  Google Scholar 

  6. Ashur Y, Adler R, Rowe M, Shouval D (1999) Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. Vaccine 17(18):2290–2296

    Article  CAS  PubMed  Google Scholar 

  7. Wagner G, Lavanchy D, Darioli R et al (1993) Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. Vaccine 11(10):1027–1032

    Article  CAS  PubMed  Google Scholar 

  8. Martin A, Lemon SM (2006) Hepatitis A virus: from discovery to vaccines. Hepatology 43(2 Suppl 1):S164–S172

    Article  CAS  PubMed  Google Scholar 

  9. WHO position paper on hepatitis A vaccines (2012) Wkly Epidemiol Rec 87(28/29):261–276

    Google Scholar 

  10. Van Damme P, Van Herck K (2004) A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines 3(3):249–267

    Article  PubMed  Google Scholar 

  11. Vidor E, Dumas R, Porteret V, Bailleux F, Veitch K (2004) Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis 23(4):300–309

    Article  CAS  PubMed  Google Scholar 

  12. Wu JY, Liu Y, Chen JT, Xia M, Zhang XM (2012) Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive(R). Hum Vaccin Immunother 8(12):1836–1844

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhang X, An J, Tu A et al (2016) Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Hum Vaccin Immunother 12(9):2322–2326

    Article  PubMed  PubMed Central  Google Scholar 

  14. Liu XE, Wushouer F, Gou A et al (2013) Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region. China Hum Vaccin Immunother 9(7):1460–1465

    Article  CAS  PubMed  Google Scholar 

  15. Cui F, Liang X, Wang F, Zheng H, Hutin YJ, Yang W (2014) Development, production, and postmarketing surveillance of hepatitis A vaccines in China. J Epidemiol 24(3):169–177

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rao S, Mao JS, Motlekar S, Fangcheng Z, Kadhe G (2016) A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children. Hum Vaccin Immunother 12(12):3160–3165

    Article  PubMed  PubMed Central  Google Scholar 

  17. Shouval D, Ashur Y, Adler R et al (1993) Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine 11(Suppl 1):9–14

    Article  Google Scholar 

  18. Lemon SM (1993) Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J Hepatol 18(Suppl 2):S15–S19

    Article  PubMed  Google Scholar 

  19. Vallbracht A, Maier K, Stierhof YD, Wiedmann KH, Flehmig B, Fleischer B (1989) Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis 160(2):209–217

    Article  CAS  PubMed  Google Scholar 

  20. Hashimoti E, Kojimahara N, Noguchi S, Taniai M, Ishiguro N, Hayashi N (1996) Immunohistochemical characterization of hepatic lymphocytes in acute hepatitis A, B, and C. J Clin Gastroenterol 23(3):199–202

    Article  CAS  PubMed  Google Scholar 

  21. Sanchez G, Pinto RM, Bosch A (2004) A novel CD4+ T-helper lymphocyte epitope in the VP3 protein of hepatitis A virus. J Med Virol 72(4):525–532

    Article  CAS  PubMed  Google Scholar 

  22. Baba M, Fukai K, Hasegawa H, Nakayabu M, Suzuki S (1992) The role of natural killer cells and lymphokine activated killer cells in the pathogenesis of hepatic injury in hepatitis A [corrected]. J Clin Lab Immunol 38(1):1–14

    PubMed  Google Scholar 

  23. Vallbracht A, Gabriel P, Maier K et al (1986) Cell-mediated cytotoxicity in hepatitis A virus infection. Hepatology 6(6):1308–1314

    Article  CAS  PubMed  Google Scholar 

  24. Kurane I, Binn LN, Bancroft WH, Ennis FA (1985) Human lymphocyte responses to hepatitis A virus-infected cells: interferon production and lysis of infected cells. J Immunol 135(3):2140–2144

    CAS  PubMed  Google Scholar 

  25. Perrella A, Vitiello L, Atripaldi L et al (2008) Impaired function of CD4+/CD25+ T regulatory lymphocytes characterizes the self-limited hepatitis A virus infection. J Gastroenterol Hepatol 23(7 Pt 2):e105–e110

    Article  PubMed  Google Scholar 

  26. Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van Der Meeren O (2017) Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Hum Vaccin Immunother 10:1–9

    Google Scholar 

  27. Chappuis F, Farinelli T, Deckx H et al (2017) Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: a 20-year follow-up study. Vaccine 35(10):1448–1454

    Article  CAS  PubMed  Google Scholar 

  28. Mayorga O, Buhler S, Jaeger VK et al (2016) Single-dose hepatitis A immunization: 7.5-year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response. J Infect Dis 214(10):1498–1506

    Article  CAS  PubMed  Google Scholar 

  29. Uruena A, Gonzalez JE, Rearte A et al (2016) Single-dose universal hepatitis A immunization in one-year-old children in Argentina: high prevalence of protective antibodies up to 9 years after vaccination. Pediatr Infect Dis J 35(12):1339–1342

    Article  PubMed  Google Scholar 

  30. Zhang Z, Zhu X, Hu Y et al (2017) Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine. Hum Vaccin Immunother 14:1–6

    Google Scholar 

  31. Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A (1992) Simultaneous passive and active immunization against hepatitis A. Vaccine 10(Suppl 1):S138–S141

    Article  PubMed  Google Scholar 

  32. Spradling PR, Bulkow LR, Negus SE, Homan C, Bruce MG, McMahon BJ (Mar 2016) Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up. Hepatology 63(3):703–711

    Article  CAS  PubMed  Google Scholar 

  33. Werzberger A, Mensch B, Kuter B et al (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327(7):453–457

    Article  CAS  PubMed  Google Scholar 

  34. Innis BLSR, Kunasol P et al (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271:1328–1334

    Article  CAS  PubMed  Google Scholar 

  35. Mayorga Perez O, Herzog C, Zellmeyer M, Loaisiga A, Frosner G, Egger M (2003) Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 188(5):671–677

    Article  PubMed  Google Scholar 

  36. Klevens RM, Kruszon-Moran D, Wasley A et al (2011) Seroprevalence of hepatitis A virus antibodies in the U.S.: results from the national health and nutrition examination survey. Public Health Rep 126(4):522–532

    Article  PubMed  PubMed Central  Google Scholar 

  37. Dominguez A, Salleras L, Carmona G, Batalla J (2003) Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21(7–8):698–701

    Article  PubMed  Google Scholar 

  38. Hanna JN, Hills SL, Humphreys JL (2004) Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust 181(9):482–485

    PubMed  Google Scholar 

  39. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D (2005) Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294(2):202–210

    Article  CAS  PubMed  Google Scholar 

  40. Chodick G, Heymann AD, Ashkenazi S, Kokia E, Shalev V (2008) Long-term trends in hepatitis A incidence following the inclusion of hepatitis A vaccine in the routine nationwide immunization program. J Viral Hepat 15(Suppl 2):62–65

    Article  PubMed  Google Scholar 

  41. Barkai G, Belmaker I, Givon-Lavi N, Dagan R (2009) The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community. Pediatr Infect Dis J 28(5):391–393

    Article  PubMed  Google Scholar 

  42. Manor Y, Lewis M, Ram D, et al (2017) Evidence for hepatitis A virus endemic circulation in Israel despite universal toddler vaccination since 1999 and low clinical incidence in all age groups. J Infect Dis 215(4) 574–580

    Google Scholar 

  43. Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D (2017) Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines – a systematic review. Hum Vaccin Immunother 13(3):724–736

    Article  PubMed  Google Scholar 

  44. Van Damme P, Mathei C, Thoelen S, Meheus A, Safary A, Andre FE (1994) Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol 44(4):435–441

    Article  PubMed  Google Scholar 

  45. Vacchino MN (2008) Incidence of hepatitis A in Argentina after vaccination. J Viral Hepat 15(Suppl 2):47–50

    Article  PubMed  Google Scholar 

  46. Vizzotti C, Gonzalez J, Gentile A et al (2014) Impact of the single-dose immunization strategy against hepatitis A in Argentina. Pediatr Infect Dis J 33(1):84–88

    Article  PubMed  Google Scholar 

  47. Prikazsky V, Olear V, Cernoch A, Safary A, Andre FE (1994) Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 44(4):457–459

    Article  CAS  PubMed  Google Scholar 

  48. Zamir C, Rishpon S, Zamir D, Leventhal A, Rimon N, Ben-Porath E (2001) Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur J Clin Microbiol Infect Dis 20(3):185–187

    CAS  PubMed  Google Scholar 

  49. Sagliocca L, Amoroso P, Stroffolini T et al (1999) Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 353(9159):1136–1139

    Article  CAS  PubMed  Google Scholar 

  50. Victor JC, Monto AS, Surdina TY et al (2007) Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 357(17):1685–1694

    Article  CAS  PubMed  Google Scholar 

  51. Freeman E, Lawrence G, McAnulty J, Tobin S, MacIntyre CR, Torvaldsen S (2014) Field effectiveness of hepatitis A vaccine and uptake of post exposure prophylaxis following a change to the Australian guidelines. Vaccine 32(42):5509–5513

    Article  PubMed  Google Scholar 

  52. Fiore AE, Wasley A, Bell BP (2006) Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55(RR-7):1–23

    PubMed  Google Scholar 

  53. Jackson LA, Peterson D, Nelson JC et al (2013) Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics 131(2):283–289

    Article  PubMed  Google Scholar 

  54. Irving GJ, Holden J, Yang R, Pope D (2012) Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database Syst Rev 7:CD009051

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Unit, Institute of Gastroenterology and Hepatology, Jerusalem, Israel

    Daniel Shouval

  2. Division of Medicine, Hadassah-Hebrew University Hospital, Jerusalem, Israel

    Daniel Shouval

Authors
  1. Daniel Shouval
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Shouval .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, National Taiwan University College of Medicine, Taipei, Taiwan

    Mei-Hwei Chang

  2. Department of Pediatrics, Johns Hopkins University School of Mediine, Baltimore, MD, USA

    Kathleen B. Schwarz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shouval, D. (2019). Prevention of Hepatitis A. In: Chang, MH., Schwarz, K. (eds) Viral Hepatitis in Children. Springer, Singapore. https://doi.org/10.1007/978-981-13-0050-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-0050-9_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-0049-3

  • Online ISBN: 978-981-13-0050-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation